Eric Hughes
Vermogen: 4 M $ op 31-05-2026
Vermogen: 4 M $ op 31-05-2026
Dr. Eric A. Hughes is an Independent Director at Monte Rosa Therapeutics, Inc. and a Chief Medical Officer, Executive VP-Global R&D at Teva Pharmaceutical Industries Ltd. He is on the Board of Directors at Monte Rosa Therapeutics, Inc. Dr. Hughes was previously employed as a SVP-Clinical Development & Translational Medicine by Vertex Pharmaceuticals, Inc. He received his graduate degree from Yale School of Medicine and a doctorate degree from Yale School of Medicine.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-03-2026 | 107.711 ( 0,01% ) | 4 M $ | 31-05-2026 | |
| 11-06-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Hoofd Techniek/Wetenschap/O&O | 01-08-2022 |
| MONTE ROSA THERAPEUTICS, INC. | Directeur/Bestuurslid | 13-12-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Yale School of Medicine
Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau